Sentiment-Signal
18,5
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Unternehmen & Branche
| Name | Stoke Therapeutics, Inc. |
|---|---|
| Ticker | STOK |
| CIK | 0001623526 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,99 Mrd. USD |
| Beta | 1,22 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 184,420,000 | -6,885,000 | -0.12 | 418,434,000 | 352,457,000 |
| 2025-09-30 | 10-Q | 10,632,000 | -38,347,000 | -0.65 | 360,264,000 | 308,105,000 |
| 2025-06-30 | 10-Q | 13,817,000 | -23,483,000 | -0.40 | 384,508,000 | 334,943,000 |
| 2025-03-31 | 10-Q | 158,569,000 | 112,879,000 | 1.90 | 406,888,000 | 350,074,000 |
| 2024-12-31 | 10-K | 36,555,000 | -88,981,000 | -1.65 | 271,555,000 | 229,021,000 |
| 2024-09-30 | 10-Q | 4,894,000 | -26,430,000 | -0.47 | 293,319,000 | 232,113,000 |
| 2024-06-30 | 10-Q | 4,831,000 | -25,695,000 | -0.46 | 307,757,000 | 242,709,000 |
| 2024-03-31 | 10-Q | 4,216,000 | -26,374,000 | -0.57 | 205,182,000 | 140,342,000 |
| 2023-12-31 | 10-K | 8,780,000 | -104,699,000 | -2.38 | 228,342,000 | 159,565,000 |
| 2023-09-30 | 10-Q | 3,308,000 | -24,542,000 | -0.55 | 239,889,000 | 172,999,000 |
| 2023-06-30 | 10-Q | -2,481,000 | -30,654,000 | -0.69 | 256,919,000 | 190,195,000 |
| 2023-03-31 | 10-Q | 5,152,000 | -22,545,000 | -0.53 | 281,796,000 | 213,822,000 |
| 2022-12-31 | 10-K | 12,405,000 | -101,067,000 | -2.60 | 256,067,000 | 184,849,000 |
| 2022-09-30 | 10-Q | 2,905,000 | -26,111,000 | -0.66 | 277,626,000 | 204,143,000 |
| 2022-06-30 | 10-Q | 3,231,000 | -24,652,000 | -0.63 | 301,427,000 | 224,321,000 |
| 2022-03-31 | 10-Q | 3,000,000 | -24,649,000 | -0.66 | 315,938,000 | 239,977,000 |
| 2021-12-31 | 10-K | -85,805,000 | -2.34 | 238,865,000 | 217,777,000 | |
| 2021-09-30 | 10-Q | -22,597,000 | -0.60 | 253,771,000 | 237,513,000 | |
| 2021-06-30 | 10-Q | -21,967,000 | -0.60 | 264,450,000 | 255,069,000 | |
| 2021-03-31 | 10-Q | -16,793,000 | 278,908,000 | 272,465,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -8,692 | 33.64 | -292,358.90 | -59,2% | |
| 2026-03-20 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -601 | 34.41 | -20,679.15 | -4,2% | |
| 2026-03-19 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,461 | 29.99 | -43,815.39 | -8,9% | |
| 2026-03-18 | Hoitt Jason | Officer, Chief Patient Officer | Open Market Sale | -1,762 | 31.28 | -55,122.06 | -11,2% | |
| 2026-03-18 | Hoitt Jason | Officer, Chief Patient Officer | Open Market Sale | -139 | 31.79 | -4,418.64 | -0,9% | |
| 2026-03-18 | Hoitt Jason | Officer, Chief Patient Officer | Open Market Sale | -30 | 32.85 | -985.50 | -0,2% | |
| 2026-03-18 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6,100 | 31.28 | -190,831.18 | -38,6% | |
| 2026-03-18 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -483 | 31.79 | -15,353.99 | -3,1% | |
| 2026-03-18 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -103 | 32.85 | -3,383.55 | -0,7% | |
| 2026-03-18 | Leggett Thomas | Officer, Chief Financial Officer | Open Market Sale | -2,173 | 31.28 | -67,979.70 | -13,8% | |
| 2026-03-18 | Leggett Thomas | Officer, Chief Financial Officer | Open Market Sale | -172 | 31.79 | -5,467.67 | -1,1% | |
| 2026-03-18 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -334 | 31.79 | -10,617.46 | -2,2% | |
| 2026-03-18 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -4,222 | 31.28 | -132,080.20 | -26,7% | |
| 2026-03-18 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -72 | 32.85 | -2,365.20 | -0,5% | |
| 2026-03-18 | Leggett Thomas | Officer, Chief Financial Officer | Open Market Sale | -37 | 32.85 | -1,215.45 | -0,2% | |
| 2026-03-17 | Hoitt Jason | Officer, Chief Patient Officer | Open Market Sale | -748 | 33.38 | -24,964.80 | -5,1% | |
| 2026-03-17 | Leggett Thomas | Officer, Chief Financial Officer | Open Market Sale | -1,274 | 32.74 | -41,710.00 | -8,4% | |
| 2026-03-17 | Leggett Thomas | Officer, Chief Financial Officer | Open Market Sale | -922 | 33.38 | -30,772.12 | -6,2% | |
| 2026-03-17 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3,577 | 32.74 | -117,108.83 | -23,7% | |
| 2026-03-17 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,587 | 33.38 | -86,342.16 | -17,5% | |
| 2026-03-17 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -2,476 | 32.74 | -81,062.75 | -16,4% | |
| 2026-03-17 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,791 | 33.38 | -59,775.34 | -12,1% | |
| 2026-03-17 | Hoitt Jason | Officer, Chief Patient Officer | Open Market Sale | -1,033 | 32.74 | -33,819.80 | -6,8% | |
| 2026-03-13 | LEVIN ARTHUR A | Director | Open Market Sale | -605 | 36.80 | -22,264.00 | -4,5% | |
| 2026-03-10 | Krainer Adrian R. | Director | Open Market Sale | -33,243 | 39.74 | -1,320,963.79 | -267,5% | |
| 2026-03-10 | TZIANABOS ARTHUR | Director, Officer, Interim Executive Chair | Open Market Sale | -4,355 | 40.00 | -174,214.37 | -35,3% | |
| 2026-03-02 | Krainer Adrian R. | Director | Open Market Sale | -7,229 | 39.66 | -286,715.15 | -58,1% | |
| 2025-12-08 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -2,678 | 32.61 | -87,337.08 | -17,7% | |
| 2025-12-08 | Kaye Edward M. MD | Director | Open Market Sale | -8,274 | 32.52 | -269,070.48 | -54,5% | |
| 2025-12-08 | Kaye Edward M. MD | Director | Open Market Sale | -3,825 | 31.44 | -120,253.03 | -24,4% | |
| 2025-12-08 | Kaye Edward M. MD | Director | Open Market Sale | -1,331 | 33.10 | -44,061.56 | -8,9% | |
| 2025-12-08 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,300 | 31.60 | -41,074.28 | -8,3% | |
| 2025-12-05 | Kaye Edward M. MD | Director | Open Market Sale | -1,681 | 31.15 | -52,357.77 | -10,6% | |
| 2025-12-05 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,004 | 31.33 | -31,455.72 | -6,4% | |
| 2025-12-05 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -2,344 | 31.76 | -74,444.74 | -15,1% | |
| 2025-12-05 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -5,437 | 31.08 | -168,997.18 | -34,2% | |
| 2025-12-05 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,673 | 31.33 | -52,415.76 | -10,6% | |
| 2025-12-05 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,989 | 31.35 | -62,345.80 | -12,6% | |
| 2025-12-05 | Kaye Edward M. MD | Director | Open Market Sale | -500 | 31.85 | -15,923.00 | -3,2% | |
| 2025-12-05 | Kaye Edward M. MD | Director | Open Market Sale | -6,367 | 31.33 | -199,480.66 | -40,4% | |
| 2025-12-04 | Kaye Edward M. MD | Director | Open Market Sale | -5,222 | 30.76 | -160,647.00 | -32,5% | |
| 2025-12-04 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -194 | 31.32 | -6,075.38 | -1,2% | |
| 2025-12-04 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -824 | 30.76 | -25,349.12 | -5,1% | |
| 2025-12-04 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -323 | 31.32 | -10,115.20 | -2,0% | |
| 2025-12-04 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,373 | 30.76 | -42,238.29 | -8,6% | |
| 2025-12-04 | Kaye Edward M. MD | Director | Open Market Sale | -1,231 | 31.32 | -38,550.49 | -7,8% | |
| 2025-12-03 | Kaye Edward M. MD | Director | Open Market Sale | -419 | 30.34 | -12,711.62 | -2,6% | |
| 2025-12-03 | Kaye Edward M. MD | Director | Open Market Sale | -651 | 30.85 | -20,081.85 | -4,1% | |
| 2025-12-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,225 | 30.85 | -37,788.43 | -7,7% | |
| 2025-12-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -789 | 30.34 | -23,936.68 | -4,8% | |
| 2025-12-03 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,394 | 30.85 | -43,001.69 | -8,7% | |
| 2025-12-03 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -898 | 30.34 | -27,243.52 | -5,5% | |
| 2025-12-02 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,416 | 29.56 | -41,859.79 | -8,5% | |
| 2025-12-02 | Kaye Edward M. MD | Director | Open Market Sale | -661 | 29.56 | -19,540.48 | -4,0% | |
| 2025-12-02 | Kaye Edward M. MD | Director | Open Market Sale | -405 | 30.14 | -12,207.47 | -2,5% | |
| 2025-12-02 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -868 | 30.14 | -26,163.17 | -5,3% | |
| 2025-12-02 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -762 | 30.14 | -22,968.13 | -4,7% | |
| 2025-12-02 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,244 | 29.56 | -36,775.13 | -7,4% | |
| 2025-11-24 | Krainer Adrian R. | Director | Open Market Sale | -40,472 | 29.72 | -1,202,718.57 | -243,6% | |
| 2025-11-14 | Krainer Adrian R. | Director | Open Market Sale | -19,790 | 26.61 | -526,693.04 | -106,7% | |
| 2025-11-14 | Krainer Adrian R. | Director | Open Market Sale | -20,682 | 27.34 | -565,365.22 | -114,5% | |
| 2025-11-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -600 | 27.54 | -16,524.00 | -3,3% | |
| 2025-11-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3,776 | 25.22 | -95,246.58 | -19,3% | |
| 2025-11-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,455 | 26.02 | -37,859.97 | -7,7% | |
| 2025-11-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -100 | 29.35 | -2,935.00 | -0,6% | |
| 2025-10-08 | Kaye Edward M. MD | Director | Open Market Sale | -25,000 | 30.00 | -750,000.00 | -151,9% | |
| 2025-10-03 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -10,000 | 25.07 | -250,650.00 | -50,8% | |
| 2025-10-03 | Kaye Edward M. MD | Director | Open Market Sale | -42,461 | 25.09 | -1,065,206.37 | -215,7% | |
| 2025-10-01 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,343 | 23.64 | -126,316.00 | -25,6% | |
| 2025-09-03 | Kaye Edward M. MD | Director | Open Market Sale | -45,996 | 20.13 | -925,858.08 | -187,5% | |
| 2025-09-03 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -6,345 | 20.07 | -127,316.87 | -25,8% | |
| 2025-09-02 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -14,922 | 20.14 | -300,491.78 | -60,9% | |
| 2025-09-02 | Kaye Edward M. MD | Director | Open Market Sale | -14,860 | 20.14 | -299,259.60 | -60,6% | |
| 2025-09-02 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,501 | 19.87 | -109,325.22 | -22,1% | |
| 2025-08-29 | Kaye Edward M. MD | Director | Open Market Sale | -1,029 | 20.00 | -20,580.00 | -4,2% | |
| 2025-08-29 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -850 | 20.00 | -17,000.00 | -3,4% | |
| 2025-08-18 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -1,683 | 18.24 | -30,694.55 | -6,2% | |
| 2025-08-18 | Kaye Edward M. MD | Director | Open Market Sale | -12,126 | 18.24 | -221,153.99 | -44,8% | |
| 2025-08-18 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,805 | 18.24 | -51,157.59 | -10,4% | |
| 2025-08-13 | Allan Jonathan | Officer, GENERAL COUNSEL & CORP SEC | Open Market Sale | -13,712 | 15.00 | -205,680.00 | -41,7% | |
| 2025-08-01 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -4,504 | 12.82 | -57,724.16 | -11,7% | |
| 2025-07-01 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -4,503 | 11.63 | -52,379.35 | -10,6% | |
| 2025-06-04 | Skorpios Trust | 10% Owner | Open Market Sale | -3,000,000 | 10.20 | -30,600,000.00 | -6196,9% | |
| 2025-06-03 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6,471 | 10.03 | -64,892.48 | -13,1% | |
| 2025-06-02 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,745 | 10.00 | -17,450.00 | -3,5% | |
| 2025-05-02 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -22,790 | 10.03 | -228,542.68 | -46,3% | |
| 2025-05-01 | Ticho Barry | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3,841 | 10.00 | -38,410.00 | -7,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.